A purchaser experience of managing new expensive drugs: interferon beta

Rous, Elizabeth; Coppel, A; Haworth, John; Noyce, S

doi:10.1136/bmj.313.7066.1195

Cited by 12 publications

(8 citation statements)

References 6 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Much of the published literature relating to PICUs is from the USA and Australia, 168 and Figure 16 shows the number of MEDLINE references over the period 1966 to 1990, with a particular increase in the late 1980s.…”

Section: Potential Information Sources For Early Identificationmentioning

confidence: 99%

'Early warning systems' for identifying new healthcare technologies.

Robert

Stevens²,

Gabbay³

1999

Health Technology Assessment

111

View full text Add to dashboard Cite

Health Technology Assessment is indexed in Index Medicus/MEDLINE and Excerpta Medica/ EMBASE. Copies of the Executive Summaries are available from the NCCHTA web site (see overleaf). NHS R&D HTA Programme T he overall aim of the NHS R&D Health Technology Assessment (HTA) programme is to ensure that high-quality research information on the costs, effectiveness and broader impact of health technologies is produced in the most efficient way for those who use, manage and work in the NHS. Research is undertaken in those areas where the evidence will lead to the greatest benefits to patients, either through improved patient outcomes or the most efficient use of NHS resources. The Standing Group on Health Technology advises on national priorities for health technology assessment. Six advisory panels assist the Standing Group in identifying and prioritising projects. These priorities are then considered by the HTA Commissioning Board supported by the National Coordinating Centre for HTA (NCCHTA). This report is one of a series covering acute care, diagnostics and imaging, methodology, pharmaceuticals, population screening, and primary and community care. It was identified as a priority by the Methodology Panel and funded as project number 94/10/02. The views expressed in this publication are those of the authors and not necessarily those of the Standing Group, the Commissioning Board, the Panel members or the Department of Health. The editors wish to emphasise that funding and publication of this research by the NHS should not be taken as implicit support for the recommendations for policy contained herein. In particular, policy options in the area of screening will be considered by the National Screening Committee. This Committee, chaired by the Chief Medical Officer, will take into account the views expressed here, further available evidence and other relevant considerations. Reviews in Health Technology Assessment are termed 'systematic' when the account of the search, appraisal and synthesis methods (to minimise biases and random errors) would, in theory, permit the replication of the review by others.

show abstract

Section: Potential Information Sources For Early Identificationmentioning

confidence: 99%

'Early warning systems' for identifying new healthcare technologies.

Robert

Stevens²,

Gabbay³

1999

Health Technology Assessment

111

View full text Add to dashboard Cite

show abstract

“…There is no evidence to guide on whether,14 15when, or how to do this. What disease modifying treatments reduce disability, 16-19 how are they best monitored, and what proportion of the limited resources should be allocated to them?1 …”

Section: Multiple Sclerosis Service Aims and Objectivesmentioning

confidence: 99%

Services for patients with multiple sclerosis

Wade

1997

Journal of Neurology, Neurosurgery & Psychiatry

View full text Add to dashboard Cite

“…To ensure prescribing was within the guidelines, a vast communication network had to be sustained with managers, general practitioners, neurologists, the Multiple Sclerosis Society, and professional advisers in all the purchasing authorities. The workload involved was considerable (Rous et al 1996(Rous et al : 1196.…”

Section: The Case Of B-interferonmentioning

confidence: 99%

“…The drug has the effect of reducing the frequency of relapses as the disease process progresses. For this reason b-Interferon has been described as a`drug company's dream-ticket', in that MS is incurable, relatively common and that b-Interferon is fairly expensive (Rous et al 1996(Rous et al : 1195. The cost works out at approximately £10,000 per patient per year or £33,000 per relapse avoided (Richards 1996(Richards : 1159.…”

Section: The Case Of B-interferonmentioning

confidence: 99%

Governmentality and risk: setting priorities in the new NHS

Joyce

2001

Sociology Health & Illness

View full text Add to dashboard Cite

The aim of this paper is to explore priority setting issues in the British National Health Service (NHS). It focuses on the changing way in which rationing issues are managed by a sample of English health authorities in the wake of Health Service reforms and the separation of function between purchasing and providing health care. The paper employs the conceptual framework of`governmentality', associated with the French social theorist Michel Foucault, to analyse this aspect of contemporary British health policy. Governmentality analysis situates social and economic change as reflecting shifts in thè mentality' of government. The consequence of this new articulation is that the concepts of priority setting and rationing become embedded as dominant discourses and emergent practices within health policy. Equally important is the way in which the perceived shift in the formula of governance also results in a different conceptualisation of the subject of health governance based on the management of individual risk.

show abstract

A purchaser experience of managing new expensive drugs: interferon beta

Cited by 12 publications

References 6 publications

'Early warning systems' for identifying new healthcare technologies.

'Early warning systems' for identifying new healthcare technologies.

Services for patients with multiple sclerosis

Governmentality and risk: setting priorities in the new NHS

Contact Info

Product

Resources

About